title: [Wertheim-operation: 5-year survival of 501 consecutive patients with cervical cancer].
abstract: OBJECTIVE
  The purpose of this study was to assess the 5-year survival and morbidity when radical hysterectomy and pelvic lymphadenectomy with pre- and postoperative radiation have been performed for IA2-IIB stage cervical cancer.
  
  
  METHODS
  During a 10 and a half year period between July, 1990 and December, 2000, 501 consecutive radical hysterectomies with bilateral pelvic lymphadenectomies were performed by the same gynecological surgeon for stage IA2, IB, IIA and IIB carcinoma of the cervix at the I. Department of Obstetrics and Gynecology, Semmelweis University Budapest. The patients were treated by pre- and postoperative irradiation as well.
  
  
  RESULTS
  Perioperative complications apart from recurrence were minimal with no long-term morbidity. The absolute 5-year survival rates for the patients in stage IA2, IB1, IB2, IIA and IIB were 94,4%, 90,7%, 84,1%, 71,1% and 55,4%, respectively. The respective 5-year survival rates for patients without or with lymph node metastasis, were 94,5% and 33,3% in stage IB2, 81,7% and 48,7% in stage IIA and 70,2% and 36,5% in stage IIB, respectively.
  
  
  CONCLUSIONS
  Nerve-sparing radical abdominal hysterectomy with pelvic lymph node dissection and pre- and postoperative irradiation remains the treatment of choice for most patients with early-stage and even in IIB-stage cervical cancer. The radicality and extent of lymph node dissection and parametrial resection should be individualized and tailored to tumor- and patient-related risk factors.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, I Sz Szülészeti és Nogyógyászati Klinika.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Papp
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Csapó
authors.forename: Arpád
authors.initials: A
authors.lastname: Mayer
authors.forename: Petronella
authors.initials: P
authors.lastname: Hupuczi
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality* / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007044:Hysterectomy / Q000009:adverse effects* / Q000379:methods*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*